PDF herunterladen
Z Gastroenterol 2014; 52(12): 1394-1401
DOI: 10.1055/s-0034-1366781
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy

Prognostischer Einfluss der Mikrosatelliteninstabilität und p53-Überexpression bei metastasierten kolorektalen Karzinomen unter Oxaliplatin- und 5-FU-haltiger Chemotherapie
S. Nöpel-Dünnebacke
1   Department of Internal Medicine, Ruhr-University of Bochum, Knappschaftskrankenhaus, Bochum
,
K. Schulmann
2   Departement of Oncology, Klinikum Arnsberg
,
A. Reinacher-Schick
3   Departement of Hematology and Oncology, Ruhr-University of Bochum, St. Josef Hospital, Bochum
,
R. Porschen
4   Clinic of Internal Medicine, Hospital Bremen East, Bremen
,
W. Schmiegel
1   Department of Internal Medicine, Ruhr-University of Bochum, Knappschaftskrankenhaus, Bochum
,
A. Tannapfel
5   Institute of Pathology, Ruhr-University of Bochum
,
U. Graeven
6   Medizinische Klinik, Maria-Hilf-Krankenhaus, Mönchengladbach
› Institutsangaben
Weitere Informationen

Publikationsverlauf

14. November 2013

15. Juni 2014

Publikationsdatum:
04. Dezember 2014 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Purpose: The aim of this study was to evaluate the prognostic value of MSI-H and p53 overexpression in metastatic colorectal cancer (mCRC) treated with oxaliplatin and fluoropyrimidine-based first line chemotherapy.

Methods: Tumour samples were retrospectively obtained from 229 patients from a prospective randomised phase III trial of the AIO colorectal study group, comparing CAPOX and FUFOX in mCRC. Immunohistochemistry of p53 and MMR proteins as well as microsatellite analysis were performed.

Results: The incidence of MSI-H and p53 overexpression was 7.9 % and 65.4 %, respectively. MSI-H status was not correlated with ORR, PFS and OS. We observed a trend to lower DCR for MSI-H tumours (65 % vs. 85 %, p = 0.055). p53 overexpression was not correlated with DCR, ORR and PFS. The median OS of patients with tumors with p53 overexpression was significantly longer compared to tumors withhout p53 overexpression (19.6 vs. 15.8 months; p = 0.05). The post-progression survival (PPS) of p53-positive patients undergoing 2nd and/or 3rd line chemotherapy with irinotecan and/or cetuximab was significantly longer compared to p53-negative patients.

Conclusion: MSI-H tumours tend to have lower disease control rates when treated with an oxaliplatin/fluoropyrmidin combination. mCRC patients with p53 overexpression undergoing an irinotecan containing second- or third-line chemotherapy after oxaliplatin failure have a significantly longer post-progression survival compared to patients without p53 overexpression. To validate the clinical impact of p53 in patients with mCRC treated with irinotecan- and/or cetuximab further studies are needed.

Zusammenfassung

Studie: Evaluation des prognostischen Wertes von MSI-H und p53-Überexpression bei metastasierten kolorektalen Karzinomen (mKRK), die mit oxaliplatin- und fluoropyrimidin-basierter Erstlinienchemotherapie behandelt wurden.

Methodik: Retrospektiv wurden Tumorgewebeproben von 229 Patienten einer prospektiven randomisierten Phase-III-Studie der kolorektalen Studiengruppe der AIO, welche CAPOX gegen FUFOX bei mKRK verglich, analysiert. Ein immunhistochemischer Nachweis einer p53-Überexpression bzw. der MMR-Proteine sowie Mikrosatellitenanalysen wurden durchgeführt.

Ergebnisse: Die Inzidenz von MSI-H und p53-Überexpression lag bei 7,9 % bzw. 65,4 %. Der MSH-I-Status korrelierte nicht mit der ORR, dem PFS oder OS. Ein Trend unter MSI-H-Tumoren zu einer geringeren DCR war festzustellen (65 % vs. 85 %). Eine p53-Überexpression korrelierte nicht mit der DCR, ORR, oder dem PFS. Das mediane OS der Patienten mit p53-überexprimierten Tumoren war signifikant länger verglichen mit Tumoren ohne p53-Überexprimierung (19,6 vs. 15,8 Monate; p= 0,05). Das PFS der p53 überexprimierenden Patienten unter der Zweit- und Drittlinienchemotherapie mit Irinotecan und/oder Cetuximab war signifikant länger als bei Patienten ohne p53-Überexpression.

Diskussion: MSI-H Tumoren zeigten unter einer Kombinationstherapie aus Oxaliplatin/Fluoropyrimidin tendenziell eine schlechtere DCR. p53 überexprimierte mKRK unter einer irinotecanhaltigen Zweit- bzw. Drittlinienchemotherapie nach Oxaliplatinversagen hatten ein signifikant längeres PFS im Vergleich zu nicht p53 überexprimierenden Tumoren. Um die klinische Bedeutung dieser Beobachtung zu valuieren, werden weitere Studien benötigt.

Schlüsselwörter

metastasierters kolorektales Karzinom - Mikrosatelliteninstabilität - p53 - Oxaliplatin - Prognose

Key words

metastatic colorectal cancer - microsatellite instability - p53 - oxaliplatin - prognosis
 

  • References

  • 1 Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009; 10 (06) 353-358
    PubMedGoogle Scholar
  • 2 Issa J. Colon cancer: it's CIN or CIMP. Clin Cancer Res 2008; 14 (19) 5939-5940
    CrossrefPubMedGoogle Scholar
  • 3 Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad S USA 1999; 96 (15) 8681-8686
    PubMedGoogle Scholar
  • 4 Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349 (03) 247-257
    CrossrefPubMedGoogle Scholar
  • 5 Jover R, Zapater P, Castells A et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55 (06) 848-855
    CrossrefPubMedGoogle Scholar
  • 6 Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28 (20) 3219-3226
    CrossrefPubMedGoogle Scholar
  • 7 Sinicrope FA, Foster NR, Thibodeau SN et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103 (11) 863-875
    CrossrefPubMedGoogle Scholar
  • 8 Kim ST, Lee J, Park SH et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010; 66 (04) 659-667
    CrossrefPubMedGoogle Scholar
  • 9 Flejou JF, Andre T, Chibaudel B et al. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. J Clin Oncol 2013; 31 , suppl; abstr 3524
    PubMedGoogle Scholar
  • 10 Zaanan A, Fléjou J, Emile J et al. Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research 2011;
    PubMedGoogle Scholar
  • 11 Des Guetz G, Mariani P, Cucherousset J et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res 2007; 27 (04) 2715-2719
    PubMedGoogle Scholar
  • 12 Des Guetz G, Uzzan B, Nicolas P et al. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res 2009; 29 (05) 1615-1620
    PubMedGoogle Scholar
  • 13 Müller CI, Schulmann K, Reinacher-Schick A et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis 2008; 23 (11) 1033-1039
    CrossrefPubMedGoogle Scholar
  • 14 Braun MS, Richman SD, Quirke P et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26 (16) 2690-2698
    CrossrefPubMedGoogle Scholar
  • 15 Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358 (6381) 15-16
    CrossrefPubMedGoogle Scholar
  • 16 Vogelstein B. Cancer. A deadly inheritance. Nature 348 (6303) 681-682
    PubMedGoogle Scholar
  • 17 Hollstein M, Sidransky D, Vogelstein B et al. p53 mutations in human cancers. Science 1991; 253 (5015) 49-53
    CrossrefPubMedGoogle Scholar
  • 18 Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92 (03) 434-444
    PubMedGoogle Scholar
  • 19 Bouzourene H, Gervaz P, Cerottini JP et al. p53 and Ki-ras as prognostic factors for Dukes’ stage B colorectal cancer. Eur J Cancer 2000; 36 (08) 1008-1015
    CrossrefPubMedGoogle Scholar
  • 20 Allegra CJ, Paik S, Colangelo LH et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21 (02) 241-250
    CrossrefPubMedGoogle Scholar
  • 21 Gallego MG, Aceñero MJ, Ortega S et al. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 2000; 43 (07) 971-975
    CrossrefPubMedGoogle Scholar
  • 22 Propat S, Chen Z, Zhao D et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer.. Ann Oncol 2006; 17 (12) 1810-1817
    CrossrefPubMedGoogle Scholar
  • 23 Zaanan A, Cuilliere-Dartigues P, Guilloux A et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2010; 21 (04) 772-780
    CrossrefPubMedGoogle Scholar
  • 24 Porschen R, Arkenau H, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25 (27) 4217-4223
    CrossrefPubMedGoogle Scholar
  • 25 Petersen S, Thames HD, Nieder C et al. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis. Colon Rectum 2001; 44 (03) 322-333 ; discussion 333–334
    CrossrefPubMedGoogle Scholar
  • 26 Kunstmann E, Vieland J, Brasch FE et al. HNPCC: six new pathogenic mutations. BMC Med Genet 2004; 5: 16
    PubMedGoogle Scholar
  • 27 Engel C, Forberg J, Holinski-Feder E et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 2006; 118 (01) 115-122
    CrossrefPubMedGoogle Scholar
  • 28 Schulmann K, Brasch FE, Kunstmann E et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 2005; 128 (03) 590-599
    CrossrefPubMedGoogle Scholar
  • 29 Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58 (22) 5248-5257
    PubMedGoogle Scholar
  • 30 Zhou XP, Hoang JM, Li YJ et al. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 1998; 21 (02) 101-107
    CrossrefPubMedGoogle Scholar
  • 31 Koopman M, Kortman GAM, Mekenkamp L et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009; 100 (02) 266-273
    PubMedGoogle Scholar
  • 32 Tejpar S, Bertagnolli M, Bosman F et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010; 15 (04) 390-404
    CrossrefPubMedGoogle Scholar
  • 33 Liang J, Huang K, Lai H et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 2002; 101 (06) 519-525
    CrossrefPubMedGoogle Scholar
  • 34 Brueckl WM, Moesch C, Brabletz T et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 23 (02) 1773-1777
    PubMedGoogle Scholar
  • 35 Chen WS, Chen JY, Liu JM et al. Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases. Int J Cancer 1997; 74 (04) 470-474
    CrossrefPubMedGoogle Scholar
  • 36 Propat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23 (03) 609-618
    PubMedGoogle Scholar
  • 37 Weekes J, Ho Y, Sebesan S et al. Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression. Int J Colorectal Dis 2010; 25 (07) 907
    CrossrefPubMedGoogle Scholar
  • 38 Yu J, Shannon WD, Watson MA et al. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005; 11 (05) 2053-2062
    CrossrefPubMedGoogle Scholar
  • 39 Crea F, Giovannetti E, Cortesi F et al. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol. Cancer Ther 2009; 8 (07) 1964-1973
    CrossrefPubMedGoogle Scholar
  • 40 Oden-Gangloff A, Di Fiore F, Bibeau F et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer 2009; 100 (08) 1330-1335
    CrossrefPubMedGoogle Scholar